Skip to main content

China Jo-Jo Drugstores Inc

For the period ended Mar 31, 2024. Filed Jul 30, 2024.

View on SEC.gov

About this filing

The yearly report of a company based outside the US. It covers much of what a 10-K does, and may follow accounting rules other than US ones.

FY2024 · Filed Jul 30, 2024

RDGT$1.00+34.1%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 20-F

☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal year ended March 31,2024

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report ________

Commission file number:001-40724

China Jo-Jo Drugstores, Inc.

(Exact name of Registrant as specified in its charter)

Not applicable

(Translation of Registrant’s name into English)

Cayman IslandsRenxin Yaju Building 5 Floor 4 Gong Shu District Hangzhou City, Zhejiang Province People’s Republic of China, 310008
(Jurisdiction of incorporation or organization)(Address of principal executive offices)

Lei Liu

Renxin Yaju Building 5 Floor 4 Gong Shu District

Hangzhou City, Zhejiang Province

People’s Republic of China,310008

Tel:+86-571-88219579

(Name, telephone, Email and/or facsimile number and address of company contact person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Ordinary shares, par value $0.24 per shareCJJDNasdaq Capital Market

Securities registered or to be registered pursuant to Section 12(g) of the Act:

none

(Title of Class)

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

none

(Title of Class)

Indicate the number of outstanding shares of each of the issuer’s classes of capital or ordinary shares as of the close of the period covered by the annual report.1,743,362 Ordinary Shares and 0 Preferred Shares outstanding as of March 31, 2024.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. ☐ Yes ☒No

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an “emerging growth company.” See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒
Emerging growth company☐

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing.

U.S. GAAP ☒International Financial Reporting Standards as issued by the International Accounting Standards Board ☐Other ☐

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17 ☐ Item 18 ☐

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes☒ No

In this annual report:

●References to the “Company”, “we”, “our” and “us” are to China Jo-Jo Drugstores, Inc., a Cayman Islands company, and its predecessor China Jo-Jo Drugstores, Inc., a Nevada corporation, and its consolidated subsidiaries, subsidiaries controlled by contract and therefore deemed as variable interest entities under U.S. GAAP;
●References to “China” or the “PRC” refers to the People’s Republic of China, excluding, for the purposes of this annual report only, Hong Kong, Macau and Taiwan;
●References to “RMB” and “Renminbi” refer to the legal currency of China;
●“US$,” “U.S. dollars,” “$,” and “dollars” refer to the legal currency of the United States;
●References to “variable interest entit[y][ies]” or “VIE[s]” refer to Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiaries of Jiuzhou Pharmacy, collectively as “HJ Group”.

Special Note Regarding Forward-looking Statements

This report contains forward-looking statements. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the registrant. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Forward-looking statements usually contain the words “estimate,” “anticipate,” “believe,” “expect,” or similar expressions, and are subject to numerous known and unknown risks and uncertainties. In evaluating such statements, prospective investors should carefully review various risks and uncertainties identified in this report, including the matters set forth under the captions “Risk Factors” and in the registrant’s other SEC filings. These risks and uncertainties could cause the registrant’s actual results to differ materially from those indicated in the forward-looking statements. The registrant undertakes no obligation to update or publicly announce revisions to any forward-looking statements to reflect future events or developments.

Although forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the heading “Risks Relating to Our Business” below, as well as those discussed elsewhere in this report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. We file reports with the Securities and Exchange Commission (the “SEC”). You can read and copy any materials we file with the SEC at our internet address at www.jiuzhou360.com. In addition, the SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including the registrant.

We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

TABLE OF CONTENTS

Part I
Item 1.Identity of Directors, Senior Management and Advisers1
Item 2.Offer Statistics and Expected Timetable1
Item 3.Key Information1
A.[Reserved]7
B.Capitalization and Indebtedness7
C.Reasons for the Offer and Use of Proceeds7
D.Risk Factors8
Item 4.Information on the Company36
A.History and Development of the Company36
B.Business Overview38
C.Organizational Structure43
D.Property, Plants and Equipment47
Item 4A.Unresolved Staff Comments47
Item 5.Operating and Financial Review and Prospects47
A.Operating Results47
B.Liquidity and Capital Resources57
C.Research and Development, Patents and Licenses, etc.57
D.Trend Information57
E.Critical Accounting Estimates58
Item 6.Directors, Senior Management and Employees58
A.Directors and Senior Management58
B.Compensation60
C.Board Practices64
D.Employees65
E.Share Ownership66
F.Disclosure of a registrant’s action to recover erroneously awarded compensation66
Item 7.Major Shareholders and Related Party Transactions67
A.Major Shareholders67
B.Related Party Transactions67
C.Interests of Experts and Counsel67
Item 8.Financial Information68
A.Consolidated Statements and Other Financial Information68
B.Significant Changes68
Item 9.The Offer and Listing68
A.Offer and Listing Details68
B.Plan of Distribution68
C.Markets68
D.Selling shareholders68
E.Dilution68
F.Expenses of the issue68
Item 10.Additional Information69
A.Share Capital69
B.Memorandum and Articles of Association69
C.Material Contracts74
D.Exchange Controls74
E.Taxation75
F.Dividends and Paying Agents76
G.Statement by Experts76
H.Documents on Display76
I.Subsidiary Information76

i

Item 11.Quantitative and Qualitative Disclosures about Market Risk76
Item 12.Description of Securities Other than Equity Securities78
A.Debt Securities78
B.Warrants and Rights78
C.Other Securities78
D.American Depositary Shares78
Part II
Item 13.Defaults, Dividend Arrearages and Delinquencies79
Item 14.Material Modifications to the Rights of Security Holders and Use of Proceeds79
Item 15.Controls and Procedures79
Item 16.[Reserved]80
Item 16A.Audit Committee Financial Expert80
Item 16B.Code of Ethics80
Item 16C.Principal Accountant Fees and Services81
Item 16D.Exemptions from the Listing Standards for Audit Committees81
Item 16E.Purchases of Equity Securities by the Issuer and Affiliated Purchasers82
Item 16F.Change in Registrant’s Certifying Accountant82
Item 16G.Corporate Governance82
Item 16H.Mine Safety Disclosure82
Item 16IDisclosure Regarding Foreign Jurisdictions That Prevent Inspections82
Item 16JInsider trading policies83
Item 16KCybersecurity83
Part III
Item 17.Financial Statements84
Item 18.Financial Statements84
Item 19.Exhibits84
Index to Consolidated Financial StatementsF-1

ii

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.